NEW YORK, September 15, 2016 /PRNewswire/ --
The global Drug Manufacturers space has seen moderate growth over the last five years due to increased demand for medicines, especially from emerging economies. This morning, Stock-Callers.com has issued research reports on four equities, namely, Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), and Apricus Biosciences Inc. (NASDAQ: APRI). Download the free research reports on these stocks today:
Pernix Therapeutics Holdings
Shares in Morristown, New Jersey headquartered Pernix Therapeutics Holdings Inc. ended Wednesday's session at $0.53, which was a decline of 1.21%. The stock recorded a trading volume of 1.81 million shares. The Company's shares have gained 18.13% in the previous three months. The stock is trading 15.28% below its 50-day moving average. Moreover, shares of Pernix Therapeutics Holdings, which develops, manufactures, markets, and sells pharmaceutical products, have a Relative Strength Index (RSI) of 40.76.
On September 14th, 2016, Pernix Therapeutics announced that the US Patent and Trademark Office has issued US Patent Numbers 9,421,200 ('200 patent) and 9,433,619 ('619 patent), covering important safety information related to dosing patients with Zohydro® ER with BeadTek™. These patents, in addition to recently issued US Patent Numbers 9,265,760 ('760 patent), 9,326,982 ('982 patent), 9,333,201 ('201 patent) and 9,339,499 ('499 patent), are broadly directed to methods of dosing patients with mild or moderate hepatic impairment with hydrocodone. The '760, '982, '201, '499, '200, and '619 patents expire on July 25th, 2033. See our free and comprehensive research report on PTX at:
New York headquartered Synergy Pharmaceuticals Inc.'s stock jumped 8.83%, closing the day at $5.30. A total volume of 5.47 million shares was traded, which was above their three months average volume of 2.80 million shares. The Company's shares have advanced 4.74% in the last one month and 43.63% in the previous three months. The stock is trading 18.68% above its 50-day moving average and 31.11% above its 200-day moving average. Additionally, shares of Synergy Pharmaceuticals, which focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases, have an RSI of 63.88.
On August 9th, 2016, Synergy Pharmaceuticals reported that net loss in Q2 2016 was $38.6 million as compared to a net loss of $33.7 million incurred in Q2 2015. As of June 30th, 2016, the company had approximately $141.2 million of cash and cash equivalents on hand as compared to approximately $111.8 million cash and cash equivalents and available for sale securities as of December 31st, 2015. SGYP free research report PDF is just a click away at:
On Wednesday, shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S recorded a trading volume of 1.77 million shares. The stock ended the day 0.46% higher at $46.05. The Company's shares are trading below their 50-day moving average by 8.73%. Furthermore, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 40.90.
On September 1st, 2016, Novo Nordisk announced that Lars Rebien Sørensen, president and chief executive officer, will retire from the company by the end of 2016. Lars Fruergaard Jørgensen, currently executive vice president and head of Corporate Development, will succeed him, effective 1st, January 2017.
On September 13th, 2016, research firm Exane BNP Paribas upgraded the Company's stock rating from 'Neutral' to 'Outperform'. Sign up for your complimentary report on NVO at:
San Diego, California headquartered Apricus Biosciences Inc.'s stock surged 8.33%, finishing yesterday's session at $0.39. A total volume of 1.61 million shares was traded, above their three months average volume of 701,420 shares. The Company's shares have advanced 30.00% in the last one month. The stock is trading above its 50-day moving average by 15.04%. Additionally, shares of Apricus Biosciences, which focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology, have an RSI of 66.28.
On September 8th, 2016, Apricus Biosciences announced that Argentina has granted Apricus` commercialization partner, Ferring Pharmaceuticals, market approval for Vitaros®, an on-demand topical cream indicated for the treatment of patients with erectile dysfunction. The company stated that it is the twenty-fourth country in which the product has been approved. Register for free on Stock-Callers.com and download the latest research report on APRI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA